Atlas Trials

A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer

Clinical trial NCT04111913 · UNKNOWN

Trial details

NCT number
NCT04111913
Sponsor
Nanfang Hospital, Southern Medical University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Unresectable Stage III Non-small Cell Lung Cancer
Start date
2019-10-01
Primary completion
2020-08-31
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.